Apex BiotechnologyTPE:1733 -0.17%81 EV-to-FCF is 17.70 as of Jul. 08, 2026, which is 21% above its 10-year median of 14.57. GuruFocus rates TPE:1733 with a GF Score™ of 81/100 and a GF Value™ of NT$30.08 (Fairly Valued). The stock has 2 warning signs investors should review. Among 327 Biotechnology companies, Apex Biotechnology ranks worse than 52.6% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Apex Biotechnology's Enterprise Value is NT$2,494 Mil.
Apex Biotechnology's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$141 Mil. Therefore, Apex Biotechnology's EV-to-FCF for today is 17.70.
The historical rank and industry rank for Apex Biotechnology's EV-to-FCF or its related term are showing as below:
TPE:1733'
s EV-to-FCF Range Over the Past 10 Years
Min: -549.22 Med: 14.57 Max: 136.37
Current: 17.67
During the past 13 years, the highest EV-to-FCF of Apex Biotechnology was 136.37. The lowest was -549.22. And the median was 14.57.
TPE:1733's EV-to-FCF is ranked worse than 52.6% of 327
companies
in the Biotechnology industry
Industry Median: 16.69
vs TPE:1733: 17.67
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Apex Biotechnology's PE Ratio (TTM) for today is calculated as:
Apex Biotechnology's share price for today is NT$29.90.
Apex Biotechnology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$1.630.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Apex Biotechnology EV-to-FCF Related Terms
Apex Biotechnology EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Apex Biotechnology's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:1733 vs VRTX, REGN, ALNY: EV-to-FCF Comparison
For the Biotechnology subindustry, Apex Biotechnology's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apex Biotechnology EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Apex Biotechnology's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Apex Biotechnology's EV-to-FCF falls into.
Apex Biotechnology's current Enterprise Value is NT$2,494 Mil.
Apex Biotechnology's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$141 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Apex Biotechnology (TPE:1733) has a EV-to-FCF of 17.70 as of Jul. 08, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Apex Biotechnology and its competitors. This is 21% above median its historical median of 14.57. According to the industry distribution chart, Apex Biotechnology ranks #172 out of 327 companies in the Biotechnology industry, placing it in the top 52.6%.
Is Apex Biotechnology's EV-to-FCF too high?
Apex Biotechnology's current EV-to-FCF of 17.70 is 21% above median its 10-year median of 14.57. The Biotechnology industry median EV-to-FCF is 16.69. Apex Biotechnology's value of 17.70 is 6.1% above this industry median. Based on the distribution chart, Apex Biotechnology ranks #172 out of 327 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Apex Biotechnology has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Apex Biotechnology's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Apex Biotechnology ranks #172 out of 327 companies for EV-to-FCF. This places Apex Biotechnology in the lower half of its industry. The industry median EV-to-FCF is 16.69. Apex Biotechnology's value of 17.70 is 6.1% above this benchmark. While the company's 10-year median is 14.57 vs. the industry median of 16.69, Apex Biotechnology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.69, based on 327 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Apex Biotechnology's current EV-to-FCF of 17.70 is 6.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Apex Biotechnology and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Apex Biotechnology's current EV-to-FCF is 17.70, which is 21% above median its own 10-year median of 14.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apex Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Apex Biotechnology (TPE:1733) is currently considered Fairly Valued. The stock's GF Value™ is NT$30.08, compared to a current price of NT$29.90 — trading 0.6% below its estimated fair value. The current EV-to-FCF is 17.70, which is 21% above median its 10-year median of 14.57 and 6.1% above the Biotechnology industry median of 16.69. Apex Biotechnology's overall GF Score™ is 81/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Apex Biotechnology (TPE:1733), the current EV-to-FCF is 17.70 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Apex Biotechnology (TPE:1733) Overvalued in 2026?
Based on GuruFocus' analysis, Apex Biotechnology stock appears to be undervalued.
The current stock price of NT$29.90 is trading 0.6% below its estimated GF Value™ of NT$30.08.
GuruFocus considers Apex Biotechnology to be Fairly Valued.
Key valuation signals for TPE:1733:
EV-to-FCF: 17.70 (21% above median its 10-year median of 14.57)
GF Value™: NT$30.08 vs. price of NT$29.90 (0.6% below fair value)
Industry Position: 6.1% above the Biotechnology median (#172 of 327)
No single metric tells the full story. See the TPE:1733 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Apex Biotechnology Corp is engaged in the research, development, production, manufacturing, and sale of biochemical testing instruments and proprietary test strips, as well as the import and export of products and components related to its core business. Its product offerings include diabetes testing kits, blood uric acid monitoring systems, blood lactate monitoring systems, blood haemoglobin monitoring systems, etc. The company generates maximum revenue from the sale of test strips, and the rest from testing meters, electrodes, and other products. Geographically, it derives maximum revenue from the USA, and the rest from Italy, Austria, Taiwan, China, and other markets.
81GF Score
Get the complete analysis for TPE:1733
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1733 has been successfully added to your 
